Funding the Expansion of Percepta® Human Clinical Trial with Blood Biomarker Analysis

Funding Request: $80K loan from BIO to incorporate pTau-217 blood biomarker testing into ongoing 154-subject clinical trial

Team Principal Investigators:

• Mark Melnykowycz, PhD - Cerebrum DAO
• Alan Snow, PhD - Cognitive Clarity, Inc.

TL;DR

We propose funding the highly sensitive pTau-217 blood biomarker test into an ongoing 154-subject human clinical trial for Percepta®, for $80k as a loan. This will provide strong, objective evidence of Percepta's ability to positively impact the core mechanisms of memory loss and neurodegeneration, strengthening its position in the market and boosting sales. The $CLAW IP Token currently captures a 20% royalty on all revenues of Percepta® plus a higher royalty rate on future international expansion to be negotiated by new market.

Summary

Neurodegenerative diseases like Alzheimer's represent a significant challenge in longevity research. To address this, Cerebrum DAO is supporting a promising brain health supplement, Percepta®, developed by Dr. Alan Snow. Percepta® is a patented dietary supplement with active ingredients PTI-00703® Cat's claw and MemorTea® oolong tea extract, which have shown effectiveness against amyloid plaques and neurofibrillary tangles in preclinical models. Cerebrum has designed a 6-month, 154-subject, placebo-controlled decentralized clinical trial to assess Percepta's impact on cognitive function.

This proposal seeks to enhance this trial by adding objective biomarker analysis. This will:

• Objectively measure Percepta's impact on pTau-217, a key biomarker for Alzheimer's pathology
• Provide robust human data to validate the supplement's mechanism, which preclinical data suggests involves the breakdown of plaques and tangles. Existing evidence shows the active ingredient has memory enhancing effects in humans: https://www.nature.com/articles/s41598-019-38645-0
• Generate a high-quality dataset linking a natural intervention to biomarker changes, which will boost supplement sales and support its future development as a therapeutic

Problem

The US brain-health supplement market is crowded with products that lack human data, weak patent positions, and opaque supply chains. Without demonstrable clinical benefit, consumer trust, payer acceptance, and strategic-buyer interest remain limited.

Solution

A 6-month, 154-subject decentralized human clinical trial of Percepta® with state-of-the-art blood biomarker analysis to generate definitive evidence of its efficacy. We will address the key challenges by:

• Cerebrum will incorporate the pTau-217 blood test, a highly sensitive and specific biomarker for Alzheimer's pathology, to measure physiological changes in response to Percepta®. A reduction in pTau-217 would provide strong evidence that the supplement is impacting the core drivers of memory loss.

• The trial uses Percepta®, a patented combination of concentrated Cat's claw (PTI-00703®) and a specific oolong tea extract (MemorTea®). Dr. Alan Snow's research indicates that the proanthocyanidins in Cat's claw are uniquely structured to act as a "wedge," breaking apart the insoluble beta-sheet structure of both amyloid plaques and tau tangles.

Opportunity

The brain and memory health supplement market is a massive, growing industry, projected to reach over $23 billion globally by 2030. However, it lacks products with strong, direct human evidence. This presents a major opportunity:

Market Differentiation: With successful trial results validated by biomarkers, Percepta® would be one of the only supplements on the market with proven efficacy in humans and a strong patent portfolio to protect it.

Increased Commercial Value: Objective proof of efficacy would make Percepta® a highly attractive acquisition target for major consumer health companies like Unilever, Nestle, or P&G, with a potential exit valuation between $50 to $100 million or higher (Such as Onnit's acquisition by Unilever): https://www.unilever.com/news/press-and-media/press-releases/2021/unilever-to-acquire-onnit/

Drug Development Pathway: Positive results would support new, stronger marketing claims and could pave the way for an FDA pathway for botanical drug status, a potential game-changer in the field.

Community and Investor Returns: The IP is tokenized as the $CLAW token, and Cerebrum DAO receives a 20% royalty on all global sales, providing a direct economic benefit to the DAO and its members from the project's success.

Patent Formulation: The $CLAW formulation is patented. Chief Scientist, Dr. Alan Snow, previously secured a 7-figure cash settlement on legal action against Joe Rogan's AlphaBrain that used the $CLAW formulation without a license: https://youtube.com/watch?t=2068&v=lxCAncE8pFg&feature=youtu.be

Scalable Production: Existing supply chains can produce 3M units per year. Currently 1 month's supply sells for $60. This yields $180M a year revenue potential without any major supply chain upgrades.

Budget

Funding request: $80,000 USD from BIO. These funds will be allocated entirely to incorporating pTau-217 blood biomarker testing into the ongoing clinical trial for a subset of the 154 participants at two time points (month 0 and month 6). The budget covers the cost of at-home sample collection kits, shipping, logistics, and the final assay analysis performed by Quanterix.

IP & Open Science Roadmap

Tokenized & Patented IP: The project is anchored by a strong global IP portfolio, including composition of matter patents for Percepta®, which is tokenized in the NEURON-Percepta IP-NFT and governed by the $CLAW IP Token.

Open Data Reporting: All clinical trial results, including the anonymized biomarker data, will be reported to the community via Molecule's on-chain data reporting platform, ensuring transparency and providing a valuable open dataset for researchers.

Clear Commercialization Path: Cerebrum DAO holds broad commercialization rights via a JDA, including a 20% royalty on global sales. A successful trial will drive sales and unlock significant value through a potential acquisition by a major industry player.

Next Steps

1. Secure funding to integrate pTau-217 biomarker analysis into the trial protocol
2. Execute the 6-month clinical trial, which is expected to begin recruitment in August 2025
3. Collect and analyze pTau-217 blood samples at the beginning and end of the study to measure changes against placebo
4. Publish the full findings, combining cognitive and biomarker data, to scientifically validate Percepta's efficacy and share the results with the community
5. Use the findings to ramp sales in the US and enter international markets

This initiative enhances the value of $CLAW, a cash-flowing asset, and adds clinical validation that should expand sales and increase the expected value of an acquisition. By adding objective biomarker evidence to a well-designed human trial, we can validate a highly promising therapeutic for neurodegeneration and create significant value for the scientific community and project stakeholders. We invite the community to support this critical next step.

Loan Details

Total Funding: $80,000

Structure:

• 25% of funding ($20,000): In exchange for $CLAW tokens issued at the USD price of $CLAW at the time of funding
• 75% of funding ($60,000): Convertible loan with the following terms:
  • 4.25% simple annual interest rate
  • 24 month term
  • Payable in advance in whole or in parts
  • Upon term, remaining unpaid principal and interest shall auto-convert into $CLAW tokens at the USD price of $CLAW at the time the loan was funded

Additional information at [https://snapshot.box/#/s:neuron-percepta.eth/proposal/0xbc979266d5d82aea0e77d1e4e517ae211ccfa7a5ee4f0ec06e33b24b6d1e8294](Neuron-Perceptra Community Snapshot)